Molekulargenetische Diagnostik
Praxis Dr. Mato Nagel

Coumarin-Resistenz

Ein gesteigertes oder herabgesetztes Ansprechen gegenüber Vitamin-K Antagonisten kann durch eine Reihe unterschiedlicher genetischer Veränderungen bedingt sein.

Gliederung

Störungen des Vitamin K-Stoffwechsels
Coumarin-Resistenz
CYP2A6
CYP2C9
CYP4F2
VKORC1
Kombinierter Mangel an Vitamin-K-abhängigen Koagulationsfaktoren Typ 1
Kombinierter Mangel an Vitamin-K-abhängigen Koagulationsfaktoren Typ 2
Pseudoxanthoma elasticum-ähnliche Erkrankung mit komplexem Gerinnungsfaktorenmangel

Referenzen:

1.

Yamano S et al. (1990) The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes.

[^]
2.

Wood AW et al. (1974) Genetic variation in coumarin hydroxylase activity in the mouse (Mus musculus).

[^]
3.

Lush IE et al. (1978) Genetic variation between mice in their metabolism of coumarin and its derivatives.

[^]
4.

Kohn MH et al. (2000) A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans.

[^]
5.

et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data.

[^]
6.

Caldwell MD et al. (2008) CYP4F2 genetic variant alters required warfarin dose.

[^]
7.

Yuan HY et al. (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

[^]
8.

Lindberg RL et al. (1992) Molecular characterization of the murine Coh locus: an amino acid difference at position 117 confers high and low coumarin 7-hydroxylase activity in P450coh.

[^]
9.

O'REILLY RA et al. (1964) HEREDITARY TRANSMISSION OF EXCEPTIONAL RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS. THE FIRST REPORTED KINDRED.

[^]
10.

Shikata E et al. (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity.

[^]
11.

Rost S et al. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

[^]
12.

Takahashi H et al. (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

[^]
13.

Cooper GM et al. (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.

[^]
14.

Limdi NA et al. (2008) VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.

[^]
15.

Borgiani P et al. (2009) CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.

[^]
16.

Takeuchi F et al. (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

[^]
17.

Nebert DW et al. () The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature.

[^]
18.

Alving BM et al. (1985) Hereditary warfarin resistance. Investigation of a rare phenomenon.

[^]
19.

Vesell ES et al. (1968) Genetic control of dicumarol levels in man.

[^]
20.

O'Reilly RA et al. (1970) The second reported kindred with hereditary resistance to oral anticoagulant drugs.

[^]
21.

Pool JG et al. (1968) Warfarin resistance in the rat.

[^]
22.

Lewis RJ et al. (1967) Warfarin resistance.

[^]
23.

Greavses JH et al. (1967) Heritable resistance to warfarin in rats.

[^]
24.

Whitlon DS et al. (1978) Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition.

[^]